Abstract:Background: Epilepsy is a critically deep-rooted CNS disorder affecting above 50 million people all over the world. Thus, a safe and effective treatment that proves its worth in this ailment is urgently needed. Thiazolidine-4-ones possess the molecules to be used as anticonvulsants. The thiazolidinedione is a cyclic analogue of thiosemicarbazides and thioureas as well as a (bio)isostere of hydantoin (imidazolidine-2,4-dione), which are recognized as novel anticonvulsant designs. Aim: This study aimed to develop and evaluate a novel thiazolidine-4-one derivative by three-component condensation in one pot reaction method. Methods: A novel thiazolidine-4-one derivative was formulated by three-component condensation. The selected OH (Alcohol) derivatives were found to be more potent; hence, a molecular docking study against a selected target LGI1 LRR domain was performed. Various analytical tests like FTIR and H1 NMR were accomplished. The FTIR was used to validate the existence of multiple functional moieties like C-S, O-H, C=O, C-N, N=O, C-NH, C-O in the wave region from 3075 cm-1 - 1236 cm-1 and H1 NMR was employed to ascertain if the synthesized analogues had the complete set of protons. Then, the anti-seizure activity of the selected compound was examined using PTZ models in mice at three successive doses, i.e., 25, 50, and 100mg/kg, and compared with standard ethosuximide. Results: The docking simulations were initiated using PyMOL after the binding site was determined and the receptor and ligand were suitably prepared. It showed higher binding frequency in comparison to the standard marketed drug Ethosuximide. FTIR and H1 NMR spectroscopy were used to characterize the chemical components. Numerous functional groups, including O-H (alcohol), C=O (ketones), N=O, C-NH, C-N, C-S, and C-O bending stretching, were visible in the synthesized molecule accordingly. The synthesized compound was effective in inhibiting the convulsions at the concentration of 100 mg/kg. Conclusion: The novel thiazolidine-4-one derivative showed promising activity and could be considered for further investigation and dosage form preparation.

Synthesis of a Series of 4-Benzyloxyaniline Analogues As Neuronal N-type Calcium Channel Blockers with Improved Anticonvulsant and Analgesic Properties.

A modulator of the low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.

Synthesis and Biological Activity of Novel L-Amino Acid Based Analgesic Compounds

Scaffold-based design and synthesis of potent N-type calcium channel blockers

T-type calcium channel blockers: a patent review (2012–2018)

Design, synthesis, biological evaluation, homology modeling and docking studies of (E)-3-(benzo[d][1,3]dioxol-5-ylmethylene) pyrrolidin-2-one derivatives as potent anticonvulsant agents

Synthesis and Evaluation of Anticonvulsant Activities of 4-Phenylpiperidin- 2-One Derivatives

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy

Design, Synthesis, And Pharmacological Evaluation Of Analogues Derived From The Plev Tetrapeptide As Protein-Protein Interaction Modulators Of Voltage-Gated Sodium Channel 1.6

Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel

Synthesis and Biological Evaluation of Novel Σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones

Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy

Discovery of α‐Obscurine Derivatives as Novel Cav3.1 Calcium Channel Blockers

Design, Synthesis and Pharmacological Evaluation of Novel N-(2-(1, 1-Dimethyl-5, 7-Dioxo-4, 6-Diazaspiro[2.4]heptan-6-yl)ethyl) Sulfonamide Derivatives As Potential Anticonvulsant Agents.

2-Aminopyridines as Potent and Selective Na v 1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model

Chimeric Agents Derived from the Functionalized Amino Acid, Lacosamide, and the Α-Aminoamide, Safinamide: Evaluation of Their Inhibitory Actions on Voltage-Gated Sodium Channels, and Antiseizure and Antinociception Activities and Comparison with Lacosamide and Safinamide

Synthesis and Pharmacological Evaluation of Novel Benzenesulfonamide Derivatives As Potential Anticonvulsant Agents.

Molecular Pharmacology of Selective Na V 1.6 and Dual Na V 1.6/Na V 1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo

Thiazolidine-4-one Analogues: Synthesis, In-Silico Molecular Modeling, and In-vivo Estimation for Anticonvulsant Potential

Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues

Design, Synthesis and Mechanism of Action of Novel Μ-Conotoxin KIIIA Analogs for Inhibition of the Voltage-Gated Sodium Channel Nav1.7.